The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has adopted a positive opinion, recommending the granting of a marketing authorisation, for Ellaone® tablets (ulipristal acetate 30 mg), indicated for emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure. Ulipristal acetate is a synthetic selective progesterone receptor modulator with antagonistic and partial agonistic effects at the progesterone